These results were consistent with the flow cytometric analyses (Tregs: 2.0 ± 1.0% in controls versus 3.9 ± 1.3% in neuropathic pain, P = 0.007; relative FoxP3 mRNA expression: 0.6 ± 0.2 in controls versus 1.2 ± 0.8 in neuropathic pain, P = 0.028; relative TGF-β mRNA expression: 0.15 ± 0.06 in controls versus 0.25 ± 0.15 in neuropathic pain, P = 0.009; Figure 4). The gene discussed is FOXP3; the disease is neuropathic pain.